凯莱英(6821.HK)盘中一度跌4.75%报97.35港元，市值351.4亿港元。联交所最新权益披露资料显示，凯莱英于9月16日遭Norges Bank在场内以每股均价 104.5283港元减持26.28万股，涉资约2747万港元。减持后，其持股比例由14.51%下降至13.56%。(格隆汇) | 表格序號 | 大股東/董事/最高行政人員名 | 作出披露的 買入 / 費出或涉及的 | | 每股的平均價 | 持有權益的股份數目 | | 佔已發行的 有關事件的日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 股份數目 原因 | | | (請參閱上述*註 | | 有投票權股 (日 / 月 / 年) | | | | | | | 1 | | 份百分比 1 % ) | | CS20250917E00436 | Norges Bank | 1201(L) | 262,800(L) | HKD 104.5283 | | 3,735,400(L) | 13.56(L)16/09/2025 | | | | ■ 肌菜英 分时 多日 日K 周K 月K 季K 年 ...

格隆汇9月19日丨根据联交所最新权益披露资料显示，2025年9月16日，凯莱英(06821.HK)遭Norges Bank在场内以每股均价104.5283港元减持26.28万股，涉 资约2747万港元。 减持后，Norges Bank最新持股数目为373.54万股，持股比例由14.51%下降至13.56%。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 材 | | | | | | | 解) | | 份百分比 | | Company of Canadian Carder Station Company of Children | | | | | and and other for a local of can and research and any and the commens ...

香港联交所最新数据显示，9月16日，Norges Bank减持凯莱英（002821）(06821)26.28万股，每股作价 104.5283港元，总金额约为2747万港元。减持后最新持股数目为373.54万股，最新持股比例为13.56%。 ...

智通财经APP获悉，香港联交所最新数据显示，9月16日，Norges Bank减持凯莱英(06821)26.28万股，每 股作价104.5283港元，总金额约为2747万港元。减持后最新持股数目为373.54万股，最新持股比例为 13.56%。 ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 136.15 CNY based on a valuation of 35 times the expected earnings per share in 2026 [3][10]. Core Views - The company has established a strong foundation in small molecule CDMO (Contract Development and Manufacturing Organization) services and is gradually entering a harvest phase with its emerging businesses. The dual growth drivers are expected to position the company as a leading technology-driven one-stop CDMO service provider [2][8]. Summary by Sections Small Molecule CDMO - The small molecule CDMO business is the cornerstone of the company's operations, leveraging advanced technologies such as continuous reaction and biocatalysis to create competitive advantages in cost and efficiency. The company is expected to maintain steady growth in this segment due to increasing demand for high-value orders and expansion into international markets [9][26]. - In 2024, the small molecule business is projected to generate revenue of 45.71 billion CNY, with a gross margin of 47.95%. The company anticipates 12 projects in the validation phase for 2025, ensuring a robust order backlog for sustained growth [26][49]. Emerging Businesses - The company has diversified into several emerging business segments, including chemical macromolecule CDMO, clinical CRO (Contract Research Organization), and biopharmaceutical services. These segments are expected to contribute significantly to revenue growth, with the emerging business generating 12.26 billion CNY in 2024, reflecting a year-on-year growth of 2.25% [57][60]. - The chemical macromolecule CDMO segment, which includes peptides and oligonucleotides, is experiencing rapid commercialization, with a revenue increase of 13.3% in 2024 [59]. Financial Projections - The company is projected to achieve net profits of 11.70 billion CNY, 14.04 billion CNY, and 17.00 billion CNY for the years 2025, 2026, and 2027, respectively, with corresponding growth rates of 23.3%, 20.0%, and 21.1% [10][16]. - Earnings per share (EPS) are expected to rise from 3.24 CNY in 2025 to 4.71 CNY by 2027, indicating a strong upward trajectory in profitability [10][16]. Market Position and Strategy - The company aims to enhance its global footprint by expanding its production capabilities in Europe and Japan, particularly through the acquisition of the Sandwich Site in the UK, which is expected to bolster its service offerings and client penetration in these regions [54][56]. - The report highlights the company's commitment to maintaining a high level of research and development investment, which is crucial for sustaining its competitive edge in the rapidly evolving pharmaceutical landscape [21][22].

Group 1 - The company held its fifth board meeting on September 15, 2025, where all nine directors attended and approved the proposal to use temporarily idle raised funds for cash management [2][3] - The board approved the use of up to 600 million RMB of temporarily idle A-share raised funds to purchase low-risk, high-liquidity principal-protected financial products, with a usage period of 12 months from the date of approval [7][15] - The company has previously used idle raised funds for cash management, with a total of 1,655.61 million RMB utilized as of July 31, 2025, and has received 66.34 million RMB in returns from these investments [8][10] Group 2 - The company aims to improve the efficiency of idle raised funds and increase financial returns through investments in short-term, low-risk financial products [11][14] - The investment will be managed by the company's management team, with the finance department responsible for specific operations [11][15] - The company will ensure that the investment does not affect the normal construction of fundraising projects and daily operational needs [14]

| 股份代號: 06821 --------- | | | --- | --- | | 上市法國名稱: 飢梨英醫與鳳凰(天津)股份有限公司 - H股 | | | 日期(日/月/年): 16/08/2025 - 16/09/2025 | | | 如欲誤看技醫權益過知之内容,請於「有關學件的日期」欄接下有關連結 · | | | *赶解:(L)-好禽(S)-汉章,(P)-可供值出的股份 | | | 製格序數 大泉車/鹽聯/最重行政人員名 作出获國的 夏入 / 寶出國志及的 蜘裂的平均價. | 持旁推动的段份數目 佔已發行的 有服裝炸的日期相關速量級份 豐權提權益 | | 新发图 | (商品開放-5) 日 有货量情段(日/月/生) 推荐 | | | 分目分析 | | | | 格隆汇9月16日丨根据联交所最新权益披露资料显示，2025年9月11日，凯莱英(06821.HK)获Schroders PLC在场内以每股均价96.7494港元增持19.76万股，涉资约1912万港元。 增持后，Schroders PLC最新持股数目为569.29万股，持股比例由19.94%上升至20.66%。 ...

Core Viewpoint - The company announced the approval of a proposal to utilize part of its temporarily idle raised funds for cash management, allowing for investment in low-risk financial products up to RMB 800 million [1] Group 1 - The fourth meeting of the fourth board of directors is scheduled for September 30, 2024 [1] - The company and its subsidiaries will ensure the normal implementation of fundraising projects and the safety of funds before using the idle funds [1] - The investment period for the financial products is set to be within 12 months after the board's approval [1] Group 2 - The funds can be rolled over within the approved limit of RMB 800 million [1] - The financial products to be purchased are characterized by high safety, good liquidity, and low risk [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年九月十五日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董事孫 雪嬌博士、侯欣一博士及謝維愷先生組成。 二、募集资金使用情况及暂时闲置原因 （一）募集资金使用情况 第一创业证券承销保荐有限责任公司 截至 2025 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年九月十五日 凯莱英医药集团（天津）股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司(以下简称"公司")于 2025 年 9 月 15 日召开第五届董事会第三次会议，审议通过了《关于使用暂时闲置募集 ...